Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EMD 72000

Known as: EMD-72000, EMD72000 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Epidermal growth factor receptor (EGFR) imaging in brain tumors is essential to visualize overexpression of EGFRvIII variants as… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
An increasing number of therapeutic antibodies targeting tumors that express the epidermal growth factor receptor (EGFR) are in… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2008
2008
Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy, and monoclonal antibodies… Expand
2008
2008
Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2007
Highly Cited
2007
OBJECTIVE The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR… Expand
2005
2005
The purpose of our research was to investigate the antiangiogenic effect of the epidermal growth factor receptor monoclonal… Expand
2005
2005
3151 Background: A high proportion of ovarian tumors express the epidermal growth factor receptor (EGFR). Preclinical and… Expand
2005
2005
3077 Background: Matuzumab is a humanized monoclonal antibody binding to the EGFR with higher affinity than natural ligands (eg… Expand
Highly Cited
2004
Highly Cited
2004
PURPOSE To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the… Expand
2004
2004
3061 Background: Monoclonal antibody EMD 72000 blocks ligand binding and inhibits EGFR activation and signal transduction. EGFR… Expand